News/Companies/CALC

CALC News

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:CALC) LA JOLLA, Calif., Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory...

September 2, 2025Conference

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

May 15, 2025

CalciMedica Q1 EPS $(0.36) Misses $(0.31) Estimate

May 14, 2025

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

April 1, 2025

CalciMedica Announced That The Company Has Entered Into A Credit Facility With Avenue Venture Opportunities Fund II, L.P., A Fund Of Avenue Capital Group, Providing Up To $32.5M

March 5, 2025

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

March 4, 2025

CalciMedica Presents AKI Data From A Post-Hoc Analysis Of The Phase 2 CARDEA Trial Of Auxora In Severe COVID-19 Pneumonia

March 4, 2025

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

November 14, 2024

HC Wainwright & Co. Maintains Buy on CalciMedica, Lowers Price Target to $16

November 4, 2024

Reported Earlier, CalciMedica Launches $10.2M Stock Offering Of 2.72M Shares At $3.75/Share to Advance Inflammatory Disease Research

October 31, 2024